Synaptogenix 11/14/2023 Earnings Report

Synaptogenix EPS Results

• Actual EPS: -$0.75
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Synaptogenix Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Synaptogenix Announcement Details

• Date: 11/14/2023
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Synaptogenix (NASDAQ:SNPX) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for neurological disorders driven by synaptic dysfunction. The company’s proprietary platform centers on small molecules engineered to modulate key signaling pathways in neurons, with the goal of enhancing synaptogenesis and neuroprotection. By targeting central nervous system pathways, Synaptogenix seeks to address unmet needs in diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis and other neurodegenerative conditions.

The company’s lead product candidate is a synthetically optimized analog of bryostatin, a marine-derived compound known to activate protein kinase C (PKC) pathways. Preclinical studies have shown that this candidate promotes synaptic growth, supports neuronal survival and may improve cognitive function. Synaptogenix is advancing this program through early- to mid-stage clinical trials in patients with mild to moderate Alzheimer’s disease, while also exploring additional indications across a range of neurodegenerative and neuroinflammatory disorders.

Headquartered in Birmingham, Alabama, Synaptogenix maintains strategic collaborations with academic institutions, research hospitals and contract research organizations across North America and Europe. These partnerships underpin multi-center clinical studies and enable efficient conduct of both human trials and preclinical research. The company’s facilities support Good Manufacturing Practice (GMP) production of clinical trial material as well as ongoing discovery and development activities.

Founded in 2008, Synaptogenix is guided by a leadership team composed of seasoned executives and scientific advisors with extensive backgrounds in neuroscience, drug development and regulatory affairs. Drawing on experience from major pharmaceutical and biotechnology firms, the management team is committed to executing a robust development strategy. Synaptogenix aims to translate its synaptic modulation platform into safe and effective treatments that may improve quality of life for patients suffering from debilitating neurological diseases.